About Diagnovus
Diagnovus is a Healthcare company based in Nashville (United States) founded in 2011, and was acquired by Aegis Science in January 2015. Molecular diagnostics for rare diseases are provided by Diagnovus. The company was acqui-hired. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include C3J Therapeutics, Combinati and Qantgene; 3 of its 3 listed competitors have raised funding.
Company details
Diagnovus was founded in 2011 and based in Nashville, United States. Molecular diagnostics for rare diseases were developed and offered by the company in the healthcare sector. Operations focused on three market products: a PCR-based test assessing Barretts esophageal cancer risk, a gene expression test for eosinophilic esophagitis, and a pharmacogenetic test using buccal swabs. The company was acquired by Aegis Sciences.
- Headquarters Nashville, United States
- Stage Acquired
- SectorsHealthcare
- Website diagnovus.com
- Social LinkedIn X
- Acquired by Aegis Science (Jan 2015)
- InvestorsAegis Science
& 1 more
- Acquired byAegis Science
(Jan 2015)
Funding Insights of Diagnovus
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Diagnovus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2011 | Seed | – | – |
2 investors in total: 2 institutional.
Investors in Diagnovus
Diagnovus has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Aegis Science and TriStar Health Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| tristarhealthpartners.com | ||||
Drug testing and clinical laboratory services are provided. | 1986 | aegislabs.com | Nashville, United States |
Investor details for Diagnovus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Diagnovus
3 dated milestones of Diagnovus across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Diagnovus is founded.
- Funding First funding round.
- Exit Acquired by Aegis Science.
Competitors of Diagnovus
Diagnovus has 3 listed competitors in our database, 3 of them funded. They include C3J Therapeutics, Combinati and Qantgene.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c3jtherapeutics.com | 2006 | Los Angeles, United States | $214.5M | 60 | Pathogen-specific antimicrobials are developed for microbial dysbiosis diseases. | |
| combinati.com | 2015 | Palo Alto, United States | $5.83M | Integrated digital PCR platform with microfluidic consumables is developed. | ||
| quantgene.com | 2015 | Berkeley, United States | $12.13M | Cancer screening blood tests are offered for early disease detection. |
Detailed competitors of Diagnovus
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Diagnovus
Websites that share an audience with Diagnovus (diagnovus.com).
Websites whose visitors overlap most with Diagnovus. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
google.com.br | google.com.br | 100% | #203 | – |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Diagnovus (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Diagnovus
Diagnovus was founded in 2011.
Diagnovus is headquartered in Nashville, United States. It is registered at Nashville, Tennessee, United States.
Diagnovus was founded in 2011 and based in Nashville, United States. Molecular diagnostics for rare diseases were developed and offered by the company in the healthcare sector. Operations focused on three market products: a PCR-based test assessing Barretts esophageal cancer risk, a gene expression test for eosinophilic esophagitis, and a pharmacogenetic test using buccal swabs. The company was acquired by Aegis Sciences.
Diagnovus's top competitors include C3J Therapeutics, Qantgene and Combinati.
Diagnovus has 2 investors. Key investors include Aegis Science, and TriStar Health Partners.
Yes. Diagnovus was acquired by Aegis Science in January 2015.